Teppei Yamaguchi
Nagoya, 4648681, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 45 publications
Real-world characteristics of trastuzumab deruxtecan-related interstitial lung disease in Japanese patients with breast cancer and gastric cancer.
Journal: The oncologist
Published: May 22, 2026
Five-year prognostic impact of pre-existing interstitial lung disease in non-small cell lung cancer patients treated with anti-PD-1 monotherapy: a retrospective analysis.
Journal: BMC cancer
Published: February 01, 2026
Three versus six weeks of corticosteroids for mild immune-related pneumonitis: a randomized trial.
Journal: American journal of respiratory and critical care medicine
Published: January 25, 2026
Multicenter Real-World Data on First-Line Chemoimmunotherapy in Patients With Advanced Non-Small Cell Lung Cancer and Performance Status 2: WJOG18424L.
Journal: Clinical lung cancer
Published: September 12, 2025
J-REGISTER: real-world study of Japanese patients with EGFR mutation-positive NSCLC treated with first-line afatinib.
Journal: Future oncology (London, England)
Published: June 07, 2025
Investigation of cardiotoxicity in patients treated with osimertinib: findings from the OSI-FACT study.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: January 21, 2025
Osimertinib as First-Line Treatment for Patients With Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer in a Real-World Setting: Updated Overall Survival Data (OSI-FACT-OS).
Journal: Clinical lung cancer
Published: January 01, 2025
Clinical impact of hypomagnesemia induced by necitumumab plus cisplatin and gemcitabine treatment in patients with advanced lung squamous cell carcinoma: a subanalysis of the NINJA study.
Journal: Therapeutic advances in medical oncology
Published: October 16, 2024
Long-term outcome of chemoimmunotherapy for extensive-stage small-cell lung cancer according to key clinical trial eligibility: 3-year outcomes from a prospective cohort study.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: September 22, 2024
Skin disorder within 30 days is a favorable prognostic factor in patients with lung squamous cell carcinoma treated with necitumumab plus gemcitabine and cisplatin: a sub-analysis of the NINJA study.
Journal: Therapeutic advances in medical oncology
Published: July 10, 2024
Durvalumab with etoposide and carboplatin for patients with extensive-stage small cell lung cancer and interstitial lung disease: A multicenter, open-label prospective trial.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: July 07, 2024
Candidate tumor-specific CD8+ T cell subsets identified in the malignant pleural effusion of advanced lung cancer patients by single-cell analysis.
Journal: Oncoimmunology
Published: July 02, 2024
Last Updated: 09/26/2026